These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2893391)

  • 1. Preliminary evaluation of manassantin A, a potential neuroleptic agent from Saururus cernuus.
    Rao KV; Puri VN; Diwan PK; Alvarez FM
    Pharmacol Res Commun; 1987 Sep; 19(9):629-38. PubMed ID: 2893391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further studies on the neuroleptic profile of manassantin A.
    Rao KV; Puri VN; el-Sawaf HA
    Eur J Pharmacol; 1990 Apr; 179(3):367-76. PubMed ID: 1973109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothermic response produced by manassantin A, a novel neuroleptic agent.
    Rao KV; Puri VN
    Life Sci; 1988; 42(26):2717-20. PubMed ID: 2898718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
    Akhtar M; Uma Devi P; Ali A; Pillai KK; Vohora D
    Fundam Clin Pharmacol; 2006 Aug; 20(4):373-8. PubMed ID: 16867021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central action of ergometrine.
    Antkiewicz-Michaluk L
    Pol J Pharmacol Pharm; 1976; 28(6):563-70. PubMed ID: 1034920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is dopamine antagonism a requisite of neuroleptic activity?
    Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects.
    Gacsályi I; Petöcz L; Fekete MI; Bükkfálvi B; Görgenyi F; Arató M
    Pol J Pharmacol Pharm; 1988; 40(6):613-9. PubMed ID: 2908364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic-like profile of alstonine.
    Costa-Campos L; Lara DR; Nunes DS; Elisabetsky E
    Pharmacol Biochem Behav; 1998 May; 60(1):133-41. PubMed ID: 9610935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models.
    Pereira M; Siba IP; Chioca LR; Correia D; Vital MA; Pizzolatti MG; Santos AR; Andreatini R
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1636-44. PubMed ID: 21689712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic activity of 10-(4-methyl-1-piperazinyl)-thieno[3,2-b] [1,5]benzoxazepine and benzothiazepine derivatives.
    Corral C; Lissavetzky J; Valdeolmillos A; Bravo L; Darias V; Sánchez Mateo C
    Arzneimittelforschung; 1992 Jul; 42(7):896-900. PubMed ID: 1358080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cannabidiol in animal models predictive of antipsychotic activity.
    Zuardi AW; Rodrigues JA; Cunha JM
    Psychopharmacology (Berl); 1991; 104(2):260-4. PubMed ID: 1678894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics.
    Arnt J; Christensen AV
    Eur J Pharmacol; 1981 Jan; 69(1):107-11. PubMed ID: 6110555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and preliminary pharmacological assessment of novel 9-substituted pyrimidino-[2,1-f]-purines.
    Pawłowski M; Drabczyńska A; Gorczyca M; Malec D; Modzelewski J
    Pol J Pharmacol Pharm; 1991; 43(1):61-70. PubMed ID: 1771164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacological profile of mesterolone.
    Baran L; Przegaliński E
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents.
    Bristow LJ; Flatman KL; Hutson PH; Kulagowski JJ; Leeson PD; Young L; Tricklebank MD
    J Pharmacol Exp Ther; 1996 May; 277(2):578-85. PubMed ID: 8627534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine.
    Mueller K
    Pharmacol Biochem Behav; 1993 May; 45(1):71-6. PubMed ID: 8100075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of calcium channel blockers on the effects of haloperidol and phenamine in mice and rats].
    Kozlovskiĭ VL; Prakh'e IV; Kenunen OG
    Eksp Klin Farmakol; 1996; 59(3):12-5. PubMed ID: 8974575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.